Pfizer sues to halt Teva's generic Viagra

Teva apparently plans to being marketing generic Viagra in 2012.

Pharmaceuticals giant Pfizer (NYSE: PFE) has sued Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) to halt Teva's marketing of a generic version of impotence drug Viagra.

Pfizer claims the generic version infringes on its patent.

Teva has tentative approval for generic Viagra from the US Food and Drug Administration (FDA) and apparently plans to market generic Viagra in 2012.

The suit was filed in Virginia on March 24th.

Teva recently beat Pfizer in the bid to acquire German pharmaceutical company Ratiopharm. Teva will pay €3.625 billion for the company.

Shares in Teva closed at $63.57, giving a market cap of $56.26 billion.

Published by Globes [online], Israel business news - - on March 31, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018